Lifeward Closes Oratech Acquisition and Raises $10 Million in Q1 Repositioning

Overview

• Lifeward completed the equity-based purchase of Oratech, taking ownership of a protein oral delivery platform as Oramed continues to run the clinical programs with previously transferred funds.
• Management said the structure gives shareholders potential upside from ORMD-0801 oral insulin, which is expected to start a Phase II study, without adding near-term operating costs or staffing needs.
• The company raised $10 million through a convertible note, a loan that can turn into shares, and it cited an additional $6.5 million tied to the Oratech deal to strengthen liquidity and flexibility.
• Executives reported supply chain problems that slowed shipments of AlterG anti-gravity treadmills and hurt margins, and they plan to clear the backlog across the second and third quarters.
• Lifeward guided 2026 revenue to be roughly in line with 2025 and kept its main push on neurorehabilitation, including a shift to partner-led patient access and work on an upper-body exoskeleton for stroke survivors.